ArticlePLoS neglected tropical diseases2012
Dolabelladienetriol, a compound from Dictyota pfaffii algae, inhibits the infection by Leishmania amazonensis.
Article in PLoS neglected tropical diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Activity of the genusFrontiers in pharmacology · 2022Pooled it
- Recent Advances in Research on Inhibitory Effects of Seaweed Extracts Against Parasites.Marine drugs · 2025Review
- Activity of the Di-Substituted Urea-Derived Compound I-17 inPathogens (Basel, Switzerland) · 2024Article
- Marine Algal Polyphenols as Skin Protective Agents: Current Status and Future Prospectives.Marine drugs · 2023Review
- The cytokine/chemokine response inHeliyon · 2023Review
- Bioprospecting marine actinomycetes for antileishmanial drugs: current perspectives and future prospects.Heliyon · 2021Review
- Apoptosis-like cell death upon kinetoplastid induction by compounds isolated from the brown algae Dictyota spiralis.Parasites & vectors · 2021Article
- Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria.Marine drugs · 2020Review
- Metabolites from Marine Microorganisms, Micro, and Macroalgae: Immense Scope for Pharmacology.Marine drugs · 2019Review
- Spiralyde A, an Antikinetoplastid Dolabellane from the Brown AlgaMarine drugs · 2019Article
- Diterpenes from the Marine Algae of the Genus Dictyota.Marine drugs · 2018Review
- Marine Algae as Source of Novel Antileishmanial Drugs: A Review.Marine drugs · 2017Review
- Immuno-Modulatory and Anti-Inflammatory Effects of Dihydrogracilin A, a Terpene Derived from the Marine Sponge Dendrilla membranosa.International journal of molecular sciences · 2017Article
- The Brown Alga Stypopodium zonale (Dictyotaceae): A Potential Source of Anti-Leishmania Drugs.Marine drugs · 2016Article
- Natural Products: Insights into Leishmaniasis Inflammatory Response.Mediators of inflammation · 2015Review
- Marine Diterpenoids as Potential Anti-Inflammatory Agents.Mediators of inflammation · 2015Review
- Resveratrol is active against Leishmania amazonensis: in vitro effect of its association with Amphotericin B.Antimicrobial agents and chemotherapy · 2014Article
- Investigation the effect of the aqueous extract ofTropical parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy for leishmaniasis, a disease caused by Leishmania parasites, is expensive and causes side effects. Furthermore, parasite resistance constitutes an increasing problem, and new drugs against this disease are needed. In this study, we examine the effect of the compound 8,10,18-trihydroxy-2,6-dolabelladiene (Dolabelladienetriol), on Leishmania growth in macrophages. The ability of this compound to modulate macrophage function is also described. METHODOLOGY/PRINCIPAL
findingsLeishmania-infected macrophages were treated with Dolabelladienetriol, and parasite growth was measured using an infectivity index. Nitric oxide (NO), TNF-α and TGF-β production were assayed in macrophages using specific assays. NF-kB nuclear translocation was analyzed by western blot. Dolabelladienetriol inhibited Leishmania in a dose-dependent manner; the IC(50) was 44 µM. Dolabelladienetriol diminished NO, TNF-α and TGF-β production in uninfected and Leishmania-infected macrophages and reduced NF-kB nuclear translocation. Dolabelladienetriol inhibited Leishmania infection even when the parasite growth was exacerbated by either IL-10 or TGF-β. In addition, Dolabelladienetriol inhibited Leishmania growth in HIV-1-co-infected human macrophages.
conclusionOur results indicate that Dolabelladienetriol significantly inhibits Leishmania in macrophages even in the presence of factors that exacerbate parasite growth, such as IL-10, TGF-β and HIV-1 co-infection. Our results suggest that Dolabelladienetriol is a promising candidate for future studies regarding treatment of leishmaniasis, associated or not with HIV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.